The incidence of venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE) is increasing in Korea. In addition, awareness of VTE according to the incidence is improving, but how long VTE should be treated and how effective VTE patients should be managed with warfarin is not well defined. Recently, various new oral anticoagulants (NOACs) were introduced in clinical practice. The duration of anticoagulation, quality control of warfarin, and practical use of NOACs in VTE would be reviewed with evidences. ( 
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투여용량은 표 5와 같다 [6] . Table 6 ). CRNMB, clinically relevant non-major bleeding; HR, hazard ratio; VTE, venous thromboembolism; PE, pulmonary embolism; DVT, deep vein thrombosis; CI, confidence interval. VTE, venous thromboembolism; CRNMB, clinically relevant non-major bleeding; EXT, extention; HR, hazard ratio; RR, relative risk.
-Yang-Ki Kim. Current management of pulmonary thromboembolism - Examples are major cardiac surgery, insertion of pacemaker or defibrillators (resulting from the risk for pocket hematoma), neurosurgery, large hernia surgery, and major cancer/urologic/vascular surgery. Dabigatran/Rivaroxaban is stopped on day 0. The longer overlap with rivaroxaban is justified by its half-life being shorter than that of dabigatran and by the concern about thromboembolic events shortly after transitioning from rivaroxaban to warfarin. 
